Protective Effects of Edaravone on White Matter Pathology in a Novel Mouse Model of Alzheimer's Disease with Chronic Cerebral Hypoperfusion

Overview

Journal J Cereb Blood Flow Metab

Publisher Sage Publications

Specialties Cardiology & Vascular Diseases
Endocrinology
Neurology

Date 2020 Oct 27

PMID 33106078

Citations 8

Authors

Tian Feng

Toru Yamashita

Ryo Sasaki

Koh Tadokoro

Namiko Matsumoto

Nozomi Hishikawa

Koji Abe

Affiliations

Soon will be listed here.

Abstract

White matter lesions (WMLs) caused by cerebral chronic hypoperfusion (CCH) may contribute to the pathophysiology of Alzheimer's disease (AD). However, the underlying mechanisms and therapeutic approaches have yet to be totally identified. In the present study, we investigated a potential therapeutic effect of the free radical scavenger edaravone (EDA) on WMLs in our previously reported novel mouse model of AD (APP23) plus CCH with motor and cognitive deficits. Relative to AD with CCH mice at 12 months (M) of age, EDA strongly improved CCH-induced WMLs in the corpus callosum of APP23 mice at 12 M by improving the disruption of white matter integrity, enhancing the proliferation of oligodendrocyte progenitor cells, attenuating endothelium/astrocyte unit dysfunction, and reducing neuroinflammation and oxidative stress. The present study demonstrates that the long-term administration of EDA may provide a promising therapeutic approach for WMLs in AD plus CCH disease with cognitive deficits.

Citing Articles

Edaravone reduces brain injury in hepatic encephalopathy by upregulation of Nrf2/HO-1 and inhibition of NF-κB, iNOS/NO and inflammatory cytokines.

Amirshahrokhi K, Imani M Mol Biol Rep. 2025; 52(1):222.

PMID: 39937373 DOI: 10.1007/s11033-025-10343-3.

Edaravone dexborneol alleviates pericyte-mediated fibrosis depositing extracellular matrix through TGF-β1/IL-11 in cerebral small vessel disease.

Duan Q, Liu Z, Xing Y, Huang H, Zhu L, Liu J J Transl Med. 2025; 23(1):161.

PMID: 39910578 PMC: 11800546. DOI: 10.1186/s12967-025-06157-3.

Oxidative stress and chronic cerebral hypoperfusion: An overview from preclinical rodent models.

Kimura S, Iwata M, Takase H, Lo E, Arai K J Cereb Blood Flow Metab. 2024; 45(3):381-395.

PMID: 39663901 PMC: 11635795. DOI: 10.1177/0271678X241305899.

Targeting glioblastoma with a brain-penetrant drug that impairs brain tumor stem cells via NLE1-Notch1 complex.

Burban A, Sharanek A, Hernandez-Corchado A, Najafabadi H, Soleimani V, Jahani-Asl A Stem Cell Reports. 2024; 19(11):1534-1547.

PMID: 39423824 PMC: 11589194. DOI: 10.1016/j.stemcr.2024.09.007.

Recognizing Alzheimer's disease from perspective of oligodendrocytes: Phenomena or pathogenesis?.

Wang J, Zhen Y, Yang J, Yang S, Zhu G CNS Neurosci Ther. 2024; 30(3):e14688.

PMID: 38516808 PMC: 10958408. DOI: 10.1111/cns.14688.

References

Zhang L, Guo Y, Wang H, Zhao L, Ma Z, Li T . Edaravone reduces Aβ-induced oxidative damage in SH-SY5Y cells by activating the Nrf2/ARE signaling pathway. Life Sci. 2019; 221:259-266. DOI: 10.1016/j.lfs.2019.02.025. View

Brown W, Moody D, Thore C, Anstrom J, Challa V . Microvascular changes in the white mater in dementia. J Neurol Sci. 2009; 283(1-2):28-31. PMC: 2713367. DOI: 10.1016/j.jns.2009.02.328. View

Bertsch K, Hagemann D, Hermes M, Walter C, Khan R, Naumann E . Resting cerebral blood flow, attention, and aging. Brain Res. 2009; 1267:77-88. DOI: 10.1016/j.brainres.2009.02.053. View

Lee E, Yoon J, Choi J, Andika F, Lee T, Jeong Y . A mouse model of subcortical vascular dementia reflecting degeneration of cerebral white matter and microcirculation. J Cereb Blood Flow Metab. 2017; 39(1):44-57. PMC: 6311665. DOI: 10.1177/0271678X17736963. View

Brickman A . Contemplating Alzheimer's disease and the contribution of white matter hyperintensities. Curr Neurol Neurosci Rep. 2013; 13(12):415. PMC: 3874404. DOI: 10.1007/s11910-013-0415-7. View

. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis. 2003; 15(3):222-9. DOI: 10.1159/000069318. View

Rutten-Jacobs L, Tozer D, Duering M, Malik R, Dichgans M, Markus H . Genetic Study of White Matter Integrity in UK Biobank (N=8448) and the Overlap With Stroke, Depression, and Dementia. Stroke. 2018; 49(6):1340-1347. PMC: 5976227. DOI: 10.1161/STROKEAHA.118.020811. View

Yamashita T, Kamiya T, Deguchi K, Inaba T, Zhang H, Shang J . Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain. J Cereb Blood Flow Metab. 2009; 29(4):715-25. DOI: 10.1038/jcbfm.2008.164. View

Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold K, Mistl C, Rothacher S . Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A. 1997; 94(24):13287-92. PMC: 24301. DOI: 10.1073/pnas.94.24.13287. View

10.

Zhai Y, Yamashita T, Nakano Y, Sun Z, Shang J, Feng T . Chronic Cerebral Hypoperfusion Accelerates Alzheimer's Disease Pathology with Cerebrovascular Remodeling in a Novel Mouse Model. J Alzheimers Dis. 2016; 53(3):893-905. DOI: 10.3233/JAD-160345. View

11.

Reimer M, McQueen J, Searcy L, Scullion G, Zonta B, Desmazieres A . Rapid disruption of axon-glial integrity in response to mild cerebral hypoperfusion. J Neurosci. 2011; 31(49):18185-94. PMC: 4337974. DOI: 10.1523/JNEUROSCI.4936-11.2011. View

12.

Wagner D, Scheibe J, Glocke I, Weise G, Deten A, Boltze J . Object-based analysis of astroglial reaction and astrocyte subtype morphology after ischemic brain injury. Acta Neurobiol Exp (Wars). 2013; 73(1):79-87. DOI: 10.55782/ane-2013-1923. View

13.

Hirono N, Kitagaki H, Kazui H, Hashimoto M, Mori E . Impact of white matter changes on clinical manifestation of Alzheimer's disease: A quantitative study. Stroke. 2000; 31(9):2182-8. DOI: 10.1161/01.str.31.9.2182. View

14.

Bilello M, Doshi J, Nabavizadeh S, Toledo J, Erus G, Xie S . Correlating Cognitive Decline with White Matter Lesion and Brain Atrophy Magnetic Resonance Imaging Measurements in Alzheimer's Disease. J Alzheimers Dis. 2015; 48(4):987-94. PMC: 4637168. DOI: 10.3233/JAD-150400. View

15.

Brickman A, Provenzano F, Muraskin J, Manly J, Blum S, Apa Z . Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. Arch Neurol. 2012; 69(12):1621-7. PMC: 3597387. DOI: 10.1001/archneurol.2012.1527. View

16.

Bracchi-Ricard V, Lambertsen K, Ricard J, Nathanson L, Karmally S, Johnstone J . Inhibition of astroglial NF-κB enhances oligodendrogenesis following spinal cord injury. J Neuroinflammation. 2013; 10:92. PMC: 3751509. DOI: 10.1186/1742-2094-10-92. View

17.

Ueno Y, Koike M, Shimada Y, Shimura H, Hira K, Tanaka R . L-carnitine enhances axonal plasticity and improves white-matter lesions after chronic hypoperfusion in rat brain. J Cereb Blood Flow Metab. 2014; 35(3):382-91. PMC: 4348379. DOI: 10.1038/jcbfm.2014.210. View

18.

Behrendt G, Baer K, Buffo A, Curtis M, Faull R, Rees M . Dynamic changes in myelin aberrations and oligodendrocyte generation in chronic amyloidosis in mice and men. Glia. 2012; 61(2):273-86. DOI: 10.1002/glia.22432. View

19.

Hishikawa N, Yamashita T, Deguchi K, Wada J, Shikata K, Makino H . Cognitive and affective functions in diabetic patients associated with diabetes-related factors, white matter abnormality and aging. Eur J Neurol. 2014; 22(2):313-21. DOI: 10.1111/ene.12568. View

20.

Bartzokis G . Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiol Aging. 2009; 32(8):1341-71. PMC: 3128664. DOI: 10.1016/j.neurobiolaging.2009.08.007. View